Company Profile
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
Source: Cofisem - Last Update: 2026-02-19
Key Executives
| CEO Ad Interim | |
| Chief Financial Officer | |
| Director Research & Development | |
| Chief Human Resources Officer | |
| Chief Regulatory & Public Affairs Officer | |
| Head of Investor Relations | |
| General Counsel |
Source: Cofisem - Last Update: 2026-02-19
Key Figures
| Millenium | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net sales | 43,626 | 41,081 | 37,817 | 42,997 | 37,761 |
| Income from ordinary activities | 46,716 | 44,286 | 41,618 | 45,389 | 39,175 |
| Operating income | 6,344 | 7,252 | 6,960 | 10,656 | 8,126 |
| Cost of financial indebtedness net | 166 | 186 | 25 | 124 | 259 |
| Equity-accounted companies contribution to income | -155 | 60 | -136 | 68 | 39 |
| Net profit from discontinued activities | 2,874 | 64 | 338 | ||
| Net income | 7,851 | 5,618 | 5,436 | 8,484 | 6,279 |
| Net income (Group share) | 7,813 | 5,560 | 5,400 | 8,371 | 6,223 |
| Fiscal year end | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - millions | EUR - millions | EUR - millions | EUR - millions | EUR - millions |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Source: Cofisem - Last Update: 2026-02-19
Shareholder information
| Free float | |
| L'Oréal | |
| BlackRock, Inc. | |
| Employees | |
| Group-owned stock |
Source: Cofisem - Last Update: 2026-02-19
Address
Sanofi
46 Avenue de la Grande Armée
FR-75017 Paris
France
Phone number: +33 (0)1 53 77 40 00
https://www.sanofi.com/fr/investisseurs/
Source: Cofisem - Last Update: 2026-02-19
Contact
Please contact MyQuestion.Italy@euronext.com for Company Profile support.